- Catalent, headquartered in Tampa, Florida, is a leading global contract development and manufacturing organization (CDMO) that enables the development and supply of better treatments for patients worldwide, focusing on pharmaceuticals, biotech, and consumer health sectors.
- In the past year, Catalent has relocated its global headquarters from Somerset, New Jersey to Tampa, Florida, and debuted a new corporate brand emphasizing customer service excellence and a 'Patient First' mindset.
- Catalent has formed significant partnerships, including an enhanced commercial license agreement with Cartherics Pty Ltd for immune cell therapies and a global partnership with GelMEDIX for the development of iPSC-derived cell therapies targeting ocular and retinal diseases.
- Catalent's ideal buyers are pharmaceutical and biotech companies seeking reliable CDMO partners to overcome complex drug development challenges, particularly in the areas of innovative therapies and advanced manufacturing capabilities.
Catalent's workforce is organized across five distinct departments, with a total headcount of 16,900 employees. The Information Technology department is the largest, comprising three employees, followed by Engineering, Education, and Community and Social Services, each with one employee. The remaining headcount is categorized under 'Other,' which accounts for eight employees. This distribution suggests a focused yet diverse departmental structure, with a significant concentration in specialized functions.
The company's workforce is distributed across two primary locations, with Baltimore, MD, housing two employees and Middleton, WI, hosting one employee. The majority of employees, totaling 11, are categorized under 'Other,' indicating a significant remote or distributed workforce. This geographic distribution highlights a concentration in select areas while maintaining a broad operational reach across various locations.
